Table 1 Background characteristics of study participants by severity of COVID-19.
Total | Overall | Non-Severe | Severea | P valueb |
|---|---|---|---|---|
N = 456 | N = 269 | N = 187 | ||
Age group, years Range: [18–98] Median: 56 | 0.036 | |||
18–44 | 112 (24.6%) | 76 (28.3%) | 36 (19.3%) | |
45–64 | 214 (46.9%) | 126 (46.8%) | 88 (47.1%) | |
≥ 65 | 130 (28.5%) | 67 (24.9%) | 63 (33.7%) | |
Sex | 0.592 | |||
Female | 197 (43.2%) | 119 (44.2%) | 78 (41.7%) | |
Male | 259 (56.8%) | 150 (55.8%) | 109 (58.3%) | |
Race and ethnicity | 0.145 | |||
Black, non-Hispanic | 275 (60.3%) | 169 (62.8%) | 106 (56.7%) | |
White, non-Hispanic | 151 (33.1%) | 88 (32.7%) | 63 (33.7%) | |
Hispanic | 14 (3.1%) | 5 (1.9%) | 9 (4.8%) | |
Other, non-Hispanicc | 16 (3.5%) | 7 (2.6%) | 9 (4.8%) | |
Any underlying health conditionsd | 0.188 | |||
0 | 22 (4.8%) | 15 (5.6%) | 7 (3.7%) | |
1 | 64 (14.0%) | 32 (11.9%) | 32 (17.1%) | |
2 | 75 (16.4%) | 50 (18.6%) | 25 (13.4%) | |
> 2 | 295 (64.7%) | 172 (63.9%) | 123 (65.8%) | |
Underlying health conditions | ||||
Cardiac disease | 279 (61.2%) | 160 (59.5%) | 119 (63.6%) | 0.370 |
Pulmonary disease | 108 (23.7%) | 67 (24.9%) | 41 (21.9%) | 0.461 |
Neurologic disease | 109 (23.9%) | 69 (25.7%) | 40 (21.4%) | 0.294 |
Renal disease | 76 (16.7%) | 35 (13.0%) | 41 (21.9%) | 0.012 |
Liver disease | 17 (3.7%) | 8 (3.0%) | 9 (4.8%) | 0.308 |
Immunocompromised | 93 (20.4%) | 60 (22.3%) | 33 (17.6%) | 0.225 |
Diabetes mellitus | 154 (33.8%) | 89 (33.1%) | 65 (34.8%) | 0.710 |
Hematological disease | 58 (12.7%) | 38 (14.1%) | 20 (10.7%) | 0.279 |
Autoimmune disease | 64 (14.0%) | 35 (13.0%) | 29 (15.5%) | 0.450 |
Smoking historye | 140 (30.7%) | 97 (36.1%) | 43 (23.0%) | 0.003 |
Substance abuse history | 88 (19.3%) | 61 (22.7%) | 27 (14.4%) | 0.028 |
Obesity | 184 (40.4%) | 91 (33.8%) | 93 (49.7%) | < 0.001 |
Endocrine disease | 31 (6.8%) | 18 (6.7%) | 13 (7.0%) | 0.913 |
Gastrointestinal disease | 87 (19.1%) | 55 (20.4%) | 32 (17.1%) | 0.373 |
